Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-Cell Lymphoma, Leg-Type: A Case Report

Sabrina Zoli; Cinzia Pellegrini; Beatrice Casadei; Alessandro Broccoli; Lisa Argnani; Laura Nanni; Vittorio Stefoni; Pier Luigi Zinzani

doi:10.1159/000534784

Prolonged Complete Response with Lenalidomide in a Relapsed Diffuse Large B-Cell Lymphoma, Leg-Type: A Case Report

Chemotherapy. 2024;69(1):23-26. doi: 10.1159/000534784. Epub 2023 Nov 1.

Authors

Sabrina Zoli^{1

2}, Cinzia Pellegrini¹, Beatrice Casadei¹, Alessandro Broccoli^{1

2}, Lisa Argnani², Laura Nanni^{1

2}, Vittorio Stefoni^{1

2}, Pier Luigi Zinzani^{1

2}

Affiliations

¹ IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
² Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy.

PMID: 37913761
DOI: 10.1159/000534784

Abstract

Introduction: For primary cutaneous diffuse large B-cell lymphoma, leg-type (PCDLBCL-LT), there are no uniform recommendations for second-line treatment in case of relapse.

Case presentation: Here, we present the case of an elderly relapsed/refractory PCDLBCL-LT patient who obtained a prolonged clinical complete remission with lenalidomide.

Conclusion: Lenalidomide as single agent led to an unexpected long complete response with manageable toxicity.

Keywords: Leg-type; Lenalidomide; Primary cutaneous diffuse large B-cell lymphoma; Remission.

Publication types

Case Reports

MeSH terms

Aged
Humans
Leg* / pathology
Lenalidomide / therapeutic use
Lymphoma, Large B-Cell, Diffuse* / diagnosis
Lymphoma, Large B-Cell, Diffuse* / drug therapy
Neoplasm Recurrence, Local / drug therapy
Pathologic Complete Response
Treatment Outcome

Substances

Lenalidomide